Aspirin- and coumadin-related bleeding after coronary- artery bypass graft surgery
- PMID: 308334
- DOI: 10.7326/0003-4819-89-3-325
Aspirin- and coumadin-related bleeding after coronary- artery bypass graft surgery
Abstract
We studied 100 consecutive patients to evaluate the potential effect of platelet active and antithrombotic agents prescribed preoperatively on bleeding complications after coronary-artery bypass graft surgery. Preoperative hemostatic values were normal in all patients. Mean mediastinal blood loss was significantly greater in 13 patients taking aspirin (892 +/- 91 ml) and six patients taking Coumadin (warfarin sodium) (858 +/- 168 ml) within 7 days of surgery than in 64 control subjects (439 +/- 28, P less than 0.001). Less marked but similar differences (P less than 0.05) were noted with other agents inhibiting platelet function. However, in nine patients given heparin, mean mediastinal blood loss (436 +/- 61 ml) was no different from that of control subjects. The degree of mediastinal blood loss did not correlate with age, sex, mean total operative time, bypass time, or number of vessels diseased or bypassed. In addition, patients taking aspirin or Coumadin required prolonged chest tube drainage compared to those in heparin or control groups (34 +/- 4 versus 20 +/- 1 h) (P less than 0.001).
Similar articles
-
Relation of preoperative use of aspirin to increased mediastinal blood loss after coronary artery bypass graft surgery.J Thorac Cardiovasc Surg. 1978 Nov;76(5):694-7. J Thorac Cardiovasc Surg. 1978. PMID: 309032
-
Early recognition of surgically correctable causes of excessive mediastinal bleeding after coronary artery bypass graft surgery.Am J Surg. 1980 Mar;139(3):313-7. doi: 10.1016/0002-9610(80)90284-6. Am J Surg. 1980. PMID: 6965824
-
Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial.J Thorac Cardiovasc Surg. 2001 Sep;122(3):457-63. doi: 10.1067/mtc.2001.115701. J Thorac Cardiovasc Surg. 2001. PMID: 11547294 Clinical Trial.
-
Reexploration for bleeding after coronary artery bypass surgery: risk factors, outcomes, and the effect of time delay.Ann Thorac Surg. 2004 Aug;78(2):527-34; discussion 534. doi: 10.1016/j.athoracsur.2004.02.088. Ann Thorac Surg. 2004. PMID: 15276512 Review.
-
Bleeding risk factors affecting warfarin therapy in the elderly with atrial fibrillation.Dimens Crit Care Nurs. 2014 Mar-Apr;33(2):57-63. doi: 10.1097/DCC.0000000000000022. Dimens Crit Care Nurs. 2014. PMID: 24496251 Review.
Cited by
-
The efficacy and safety of a pharmacologic protocol for maintaining coronary artery bypass patients at a higher mean arterial pressure during cardiopulmonary bypass. 1998.J Extra Corpor Technol. 2013 Sep;45(3):198-206. J Extra Corpor Technol. 2013. PMID: 24303604 Free PMC article. Clinical Trial.
-
The efficacy and safety of perioperative antiplatelet therapy.J Thromb Thrombolysis. 2002 Apr;13(2):97-103. doi: 10.1023/a:1016298831074. J Thromb Thrombolysis. 2002. PMID: 12101387 Review.
-
In Vitro Investigation of Hemocompatibility of Hydrothermally Treated Titanium and Titanium Alloy Surfaces.ACS Omega. 2020 Apr 3;5(14):8108-8120. doi: 10.1021/acsomega.0c00281. eCollection 2020 Apr 14. ACS Omega. 2020. PMID: 32309720 Free PMC article.
-
The efficacy and safety of perioperative antiplatelet therapy.J Thromb Thrombolysis. 2004 Feb;17(1):21-7. doi: 10.1023/B:THRO.0000036025.07348.f1. J Thromb Thrombolysis. 2004. PMID: 15277784 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources